AU4671100A - Method of inhibiting glycation product formation - Google Patents

Method of inhibiting glycation product formation

Info

Publication number
AU4671100A
AU4671100A AU46711/00A AU4671100A AU4671100A AU 4671100 A AU4671100 A AU 4671100A AU 46711/00 A AU46711/00 A AU 46711/00A AU 4671100 A AU4671100 A AU 4671100A AU 4671100 A AU4671100 A AU 4671100A
Authority
AU
Australia
Prior art keywords
product formation
glycation product
inhibiting glycation
inhibiting
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46711/00A
Inventor
Jerry L Nadler
Samuel Rahbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of AU4671100A publication Critical patent/AU4671100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU46711/00A 1999-04-30 2000-04-28 Method of inhibiting glycation product formation Abandoned AU4671100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13192799P 1999-04-30 1999-04-30
US60131927 1999-04-30
PCT/US2000/011354 WO2000066101A2 (en) 1999-04-30 2000-04-28 Method of inhibiting glycation product formation

Publications (1)

Publication Number Publication Date
AU4671100A true AU4671100A (en) 2000-11-17

Family

ID=22451635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46711/00A Abandoned AU4671100A (en) 1999-04-30 2000-04-28 Method of inhibiting glycation product formation

Country Status (2)

Country Link
AU (1) AU4671100A (en)
WO (1) WO2000066101A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1373263T3 (en) 2001-04-05 2005-03-07 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetes-related vascular diseases
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
US20100331248A1 (en) * 2008-01-31 2010-12-30 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6316458B1 (en) * 1999-04-30 2001-11-13 Cell Therapeutics, Inc. Method of enhancing insulin action

Also Published As

Publication number Publication date
WO2000066101A2 (en) 2000-11-09
WO2000066101A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
AU1774401A (en) System and method for product yield prediction
EP1143953A3 (en) Method of inhibiting angiogenesis
AU2001284697A1 (en) Method of synthesizing diketopiperazines
AU2002235412A1 (en) Method and system for product selection
AU5439401A (en) Product pusher
WO2001040970A8 (en) Method and system for selecting product colors
AU1488501A (en) Methods of inhibiting metastasis
AU3030799A (en) Smokable product
AU4671100A (en) Method of inhibiting glycation product formation
AU3512400A (en) Novel post-amadori inhibitors of advanced glycation reactions
AU6051900A (en) Product substitution search method
AU2001271016A1 (en) Method for degreasing formed product from powder
AU2224001A (en) Hologram forming method
AU3012101A (en) Method for the production of polyamides
AU6997800A (en) Method for product assurance
AU4758400A (en) Method for the production of polyamides
AU3161701A (en) Method for producing nitroguanidine
AU7023300A (en) Product and method
AU2001245959A1 (en) Food product method of preparation
AU1859301A (en) Method of forming product rolls
AU1487201A (en) Method and system for selecting product colors
AUPQ165199A0 (en) Product and process
EP1090749A3 (en) Method for producing superelastic layered products
AU1278101A (en) Product identification
AU2001271080A1 (en) Crystalline mannose and method for production thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase